Triflamides: Elimination of the triflyl anion versus substitution of the trifluoromethide group
摘要:
Base-induced elimination of CF3SO2- and nucleophilic substitution of CF3- were observed in the reaction of secondary triflamides with alkyllithium reagents.
Safe and Scalable Syntheses of N,N-Dimethyltrifluoromethanesulfonamide (DMTMSA) and Other Trifluoromethanesulfonamide Solvents for High Energy Density Battery Applications
1,2-Difunctionalization of Aryl Triflates: A Direct and Modular Access to Diversely Functionalized Anilines
作者:Seoyoung Cho、Qiu Wang
DOI:10.1021/acs.orglett.0c00320
日期:2020.2.21
ortho-Amino difunctionalization of aryl triflates has been achieved via a three-component reaction. The cascade reaction proceeds through a zincate base-mediated deprotonative formation of a reactive aryne intermediate, in situ nucleophilic addition, and coupling with electrophilic partners. This strategy leverages the advantageous reactivity of organozincate intermediates, enabling the installation
[EN] NOVEL SULPHONES FOR INHIBITION OF GAMMA SECRETASE<br/>[FR] NOUVEAUX SULFONES PERMETTANT D'INHIBER GAMMA SECRETASE
申请人:MERCK SHARP & DOHME
公开号:WO2004031138A1
公开(公告)日:2004-04-15
The invention provides compounds of formula (I) : which are inhibitors of Ϝ-secretase and hence useful in the treatment or prevention of Alzheimer's disease.
ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH
申请人:The Regents of the University of Michigan
公开号:US20190144442A1
公开(公告)日:2019-05-16
Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
The invention relates to compounds of Formulae I-III and their therapeutic uses.
这项发明涉及到I-III式化合物及其治疗用途。
[EN] INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS<br/>[FR] DÉRIVÉS D'INDAZOLE À UTILISER EN TANT QU'AGONISTES INVERSES DE CB-1
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2017034872A1
公开(公告)日:2017-03-02
The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.